Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

non-alcoholic steatohepatitis drugs

- PMLiVE

Third strike for BMS’ Opdivo in brain cancer

Despite failing first endpoint, trial is set to continue

Celgene building

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Currently in the middle of merger

Bristol Myers Squibb logo

Opdivo trial overshadows BMS financial results

Hope remains in Celgene merger

- PMLiVE

Gilead continues its exec clear-out, licenses antivirals from Novartis

Long-standing R&D chief to depart

- PMLiVE

Gilead strikes $5.1bn deal to bolster ties with Galapagos

Big boost for Belgian biotech, without a buy-out

- PMLiVE

AbbVie CEO Gonzalez defends Allergan takeover

Group's revenues will replace Humira loss

- PMLiVE

AbbVie to acquire Allergan for $63bn

Deal based on major cuts and diversified portfolio

- PMLiVE

25 Women Leaders in UK Healthcare (part 2)

25 Women in UK healthcare, Part 2   (Click here for Part 1)13. SORAYA BEKKALI Gene therapy pioneerCell and gene therapy is definitely the most exciting development in biopharma research, promising...

- PMLiVE

Gilead unveils plan to separate Kite cell therapy unit

Comes as Yescarta misses analyst expectations

- PMLiVE

Gilead’s NASH drug fails again

Drug failed to match results from placebo group

- PMLiVE

Gilead drives NASH development with insitro collaboration

Announcement comes days after Novo Nordisk deal

- PMLiVE

Allergan wins support against dissident shareholders

Shareholders vote on 1 May

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links